Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6813—Hybridisation assays
  • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
  • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Definitions

• the present invention relates to a detection system (FIG. 1) comprising a carrier (component (a)) and a detection unit component (b) bound to the carrier, which has a constant region (A) and an adjacent variable region (B). contains, and a component (c) comprising a region complementary to region (A) and (B) and one, optionally via a suitable
• the invention further relates to a method for producing such detection systems and to methods for investigating molecular interactions using the detection systems
• a human cell there are generally up to about 30,000 genes which characterize the current state of the cell.
• the state of a cell can represent, for example, an increased cell division in the case of a cancer cell or generally changed metabolic activities in the disease state.
• the activity of a gene can be, for example, via its mRNA as a transcription product or via the corresponding protein as a translation product can be determined.
• the mRNA or protein profile of a cell therefore reflects its current state
• CONFIRMATION COPY To directly characterize the protein profile in a cell, the cellular proteins must be separated from one another.An efficient method is, for example, two-dimensional polyacrylamide gel electrophoresis (2DE). In the first dimension, the proteins are classified according to their isoelectric point (IP) and in the second dimension The proteins are separated by their molecular weight. The proteins are then visualized by staining in the 2D gel, in which approximately 1,000-2,000 proteins are stained as spots in typical 2D gels. The result is a protein pattern or profile that is significant for each cell , which reflects the respective state of the cell at the protein level.
• 2DE two-dimensional polyacrylamide gel electrophoresis
• Each protein in a cell has a protein-specific position on the 2D gel, so that a so-called proteome map can be created for the cell and consequently for the whole organism of line changes eg in disease processes to be confirmed
• the protein profiles of healthy and diseased cells are compared in order to determine any differences.
• arrays are arrangements of immobilized recognition species that play an important role especially in analysis and diagnostics in the simultaneous determination of analytes. Examples are nucleic acid arrays (see e.g. B Southern et al Genomics (1992) 13 1008 U.S. Patent No. 5,632,957 WO97 / 27317 or EP-A1-0 543 550) or peptide arrays (Fodor et al, Nature 1993 364 555).
• WO96 / 01836 describes an array of DNA molecules of different sequence described the for the detection of
• nucleic acids are hybridized in a sample on a nucleic acid array on a semiconductor chip using an electrical field and subsequently not - or unspecifically-bound nucleic acids removed by a simple reversal of the polarity of the electric field.
• a mismatching of a single base pair can be recognized by a precise adjustment of the electric field strength
• the object of the present invention was to provide a recognition system which is built up from a population of pairing system-effector-fusion molecules with the aid of which this population can be identified and characterized. Furthermore, the object of the present invention is a method for the investigation of effector-binding partner interactions
• the present invention relates to a recognition system (FIG. 1) comprising i) a carrier (component (a)) and n) at least one recognition unit (component (b)) bound to the carrier, preferably a pairing system, said recognition unit being a region ( A) with a constant sequence and a region (B) adjacent to region (A) with a variable sequence and in) associated with this a pairing system effector fusion molecule containing the recognition sequence (component (b)) complementary sequence (component (c))
• Component (a) an array in which each array position can be assigned to a defined variable region B of component (b). Starting from the different recognition units on the array surface, the respective position-specific recognition systems (components (a) - (c )) being constructed
• the term recognition unit means nucleic acids or their analogs, in particular containing pentoses, preferably a pentopyranose or pentofurinose.
• the pentose is selected from a ribose, arabinose, lyxose or xylose
• suitable nucleic acids or their Analogs are DNA, RNA, in particular mRNA or p-RNA (pyranosyl-RNA, see eg WO99 / 15539), ammocyclohexyl nucleic acids (CNA, see eg WO99 / 15509), peptidic nucleic acids (PNA, see eg WO92 / 20702 or Science (254) 1999, 1497-1500) or non-helical supramolecular nanosystems as described for example in WO98 / 25943
• the recognition unit (component (b)) hybridizes specifically with the regions of component (c) complementary to its region A and B.
• component (c) are, in particular, nucleic acid protein acceptor derivatives, preferably nucleic acid puromycin derivatives or Fusagens like nucleic acid
• Protein fusion molecules in particular nucleic acid-puromycin-protein fusion molecules. Particularly preferred are fusion molecules from the nucleic acids RNA and DNA, preferably in the fusion with puromycin and a protein.
• protein includes proteins and protein structures derived from post-translational or chemically modified amino acids such as glycosylated te, phosphorylated halogenated lipid-esterified amino acids, etc., can be built up as well as shorter peptidic amino acid sequences
• constant sequence region A is understood to mean a sequence, preferably a nucleic acid sequence based on RNA, DNA or cDNA, or else sequences of nucleic acid analogs, such as, for example, a p-RNA CNA or PNA sequence that is identical in all recognition units (components (b))
• variable sequence region B is understood to mean a sequence, preferably a nucleic acid sequence, the sequence of which is different but known in the respective regions B Nucleic acid sequence
• region (A) and / or region (B) is preferably approximately 5 to approx. 80 nucleotides, preferably approx. 5 to approx. 30 nucleotides and in particular approx. 10 to approx. 30 nucleotides for region (A) and in particular approx 7-8 nucleotides for region (B), the nucleotides in a particularly preferred embodiment deoxy ⁇ bonucleotides (d), ribonucleotides (r) or 2-
• RNAs according to the present invention cannot only be used Ribonucleotides but also be made up of 2-hydroxymethyl ⁇ bonucleotides
• a protein profile of a protein population can be characterized, for example, by selecting proteins by means of suitable nucleic acid-protein fusions.
• WO98 / 31700 describes a system in which mRNA is preferably transferred to the nucleic acid a suitable linker is bound to a protein acceptor, for example a puromycin. In this way it is achieved that shortly before the translation of the mRNA into the corresponding protein has ended, the synthesized protein can be covalently bound to its coding mRNA and thus can be closely related.
• the linker whose sequence is known is particularly advantageously suitable as a binding region to region (A) of the nucleic acid according to the invention.
• a poly T 15 strain can be used as region (A) in order to connect a linker, for example with the sequence A27CC, of a nucleic acid-protein fusion
• the linker can contain a protein acceptor, eg a tRNA amino acid analogue such as the particularly suitable puromycin.
• a protein acceptor eg a tRNA amino acid analogue such as the particularly suitable puromycin.
• Comparable systems that can be used for the present invention are described, for example, in DE19646372C1 WO98 / 16636 WO91 / 05058 US 5,843,701, WO93 / 03172 or WO94 / 13623
• variable sequences of the regions (B) of the recognition units (component (b)) must contain all possible permutations
• the preferred length of the variable sequence (region B) depends on the complexity of the population, which experience has shown to be lower in a prokaryotic cell and higher in a eukaryotic cell. For example, about 30,000 genes are active in a human cell so that in the case of an array containing all pairing system effector fusion molecules Region B - nucleic acid sequences with a length of 7-8 nucleotides in permuted order are sufficient to detect all active genes of a human cell.
• n-mer oligonucleotide The number of permutation possibilities for an n-mer oligonucleotide is known to be 4 n where n is the number of nucleotides of the oligonucleotide For the ide
• a nucleic acid with the following formula, which is bound to a carrier is therefore preferred
• X any nucleotide selected from adenosine guanosine cytosine, t ⁇ ymidine or uraci! means
• carrier is understood to mean material, in particular chip material made of semiconductors, in solid or gel-like form
• support materials are, for example, ceramics, metals, in particular semiconductors, noble metals, glasses, plastics, crystalline materials or thin layers of the support, in particular of the materials mentioned, or (b ⁇ o) molecular filaments, such as cellulose, framework proteins.
• support systems as in EP- A1-0543550 or WO99 / 15893 and in particular as in
• a particularly preferred embodiment of the The detection system according to the invention is therefore an electronic chip
• the carrier is generally covalently, quasi-covalently, supramolecularly or physically and magnetically (AR Shepard et al (1997) Nucleic Acids Res, 25, 3183-3185, No. 15) in an electric field or through a molecular sieve, preferably according to a method as in US 5 605 662 WO96 / 01836, US 5,632 957, WO97 / 12030 or W099 / 15893
• Another object of the invention is a method for producing a pairing system effector fusion molecule array, for example a Fusagen array, comprising the following method steps i) Production of an array by connecting the recognition units (components (b)) containing a region (A) with a constant sequence and a region (B) adjacent to region (A) with a variable sequence to a carrier (component (a) ), where each array position can be assigned to a recognition unit with a specific region B and n) hybridization of the recognition units (components (b)) with pairing system-effector fusion molecules (components (c)) containing one of the recognition unit (Component (b)) complementary sequence
• components (c) such as the production of a fusagen
• more than one recognition system comprising component (b) and component (c) is bound spatially separately to the carrier (component (a)), for example in separate cells, for the production of the array.
• the detection units (components (b)) can be applied directly to the support surface, for example via adsorption or via spacers known to the person skilled in the art. Special production processes are described, for example, in EP-A1- 0543550 or W099 / 15893 and in particular in US Pat.
• Arrays are preferred which include all possible permutations in region B of the recognition units (components (b))
• Preferred embodiments of the method according to the invention include detection systems which have already been described in more detail above.
• the detection systems are built up on an electronic chip, the component of the sample, for example a nucleic acid fusion with the aid of an electric field is advantageously bound to the recognition unit (component (b)) bound to a carrier, for example a nucleic acid region of component (c) with a complementary sequence.
• a precise description of such an electronic chip and its Application is described, for example, in EP-A1-0543550 or WO99 / 15893 and in particular in US Pat. No. 5,605,662 WO96 / 01836, US Pat. No. 5,632,957 or WO97 / 12030
• a suitable nucleic acid linker for example an A 27 CC
• a suitable ligase for example a T4 DNA ligase.
• the mRNA linkers are Fusions bound to nucleic acids of the recognition unit (component (b)) with the exemplary formula 3 ' - (X) 7 - s - (T 15 ) -5 ' I, preferably with the aid of an electrical field, where X selected any nucleotide from Ade ⁇ osin, Thymidm Uracil, Guanosin or Cytosin means if necessary in a further step, non- or non-specifically bound nucleic acids, preferably with the help of a reversed electric field, lower field strength than in the first step
• Another object of the invention is a method for the separation and identification of pairing system-effector-fusion molecules, preferably from complex mixtures (FIG. 2), comprising the following procedure i) Production of a pairing system-effector-fusion-molecule library (components (c) - Library), preferably a Fusagen library n) Hybridization of the pairing system-effector fusion molecules (components (c)) on an array consisting of component (a) and components (b), whose region (B) all possible permutation includes where each permutation is specifically assigned to an array position (IM) Identification of array positions at which a complex consisting of component (b) and component (c) has formed iv) Characterization of the complexes identified under in) consisting of component (b) and component (c)
• components (c)) such as the generation of a Fusage ⁇ library (components (c)) can be based on WO98 / 31700 or Roberts and
• a particular advantage of this method is that the special design of the recognition units (components (b)), also pairing system-effector-fusion molecules, in particular fusages, can be identified, in which the area complementary to component (b) is unknown one achieved by the length of the pairing system, which enables a permanent hybridization and, on the other hand, by the length of region B via which the specificity of the hybridization (meaning the same as the separation of the components (c)) can be set
• the complexes formed during the hybridization of the recognition units (component (b)) and the respective components (c) can be detected by marking the components (c). If, for example, an electronic chip (component (a)) is used, the Complexes moreover eg
• Redox processes in the environment or on the electrode or via physical measured variables such as via impedance measurement and direct current measurement or in the case of a gold chip, for example via surface plasmon resonance measurement
• Pairing system-effector fusion molecules (components (c)) with dissolution of the hybridization to component (b) by, for example, increasing the temperature, variation of the local salt concentration or preferably by modulation of the electronic formation parameters.
• Characterized sequencing The method is preferably used for the analysis of Fusagen libraries. For example, the state of various cells or tissue samples can be analyzed or compared via the nucleic acid and / or protein profile thus determined. In addition, it can be demonstrated whether a specific nucleic acid or a specific protein is present in a population Possible expression states of different lines can also be identified.
• Another object of the invention is a method for identifying interactions of one or more binding partners (components (d)) which have an affinity for specific effector units of components (c) (FIG. 3)
• Affinity in the sense of the present invention means that a component of the sample specifically interacts with the effector unit of component (c)
• Such interactions can be, in particular, specific protein-protein and / or protein-nucleic acid formations, as well as the specific bond between a chemical agent and a protein effector
• the method comprises the following method steps i) Incubation of a pairing system-effector-fusion-molecular array with a substance mixture to be analyzed containing at least one component (d) n) Identification of array positions at which a complex consisting of component (b) component ( c) and component (d) has formed m) Characterization of the complexes identified under u) consisting of component (b), component (c) and component (d)
• the complex that is formed is detected using a component (d) marking.
• a component (d) marking For example, when using an electronic chip (component (a))
• the complexes can also be identified, for example, by means of redox processes in the environment or at the electrode or by physical parameters such as impedance measurement and direct current measurement, or in the case of a gold chip, for example by surface plasmon resonance measurement
• the subcomplexes consisting of component (c) and component (d) will be sequentially separated from the individual identified complexes by dissolving the hybridization to component (b) by, for example, increasing the temperature, varying the local salt concentration or preferably by modulating the electronic one Binding parameters eluted Components (d) are now above the
• labeling methods for nucleic acids, proteins and / or chemical active substances are chemical and / or physicochemical, enzyme, protein, radioactive isotope, non-radioactive isotope, toxin, chemiluminescent and / or fluorescent labeling
• Examples of chemical substances known to the person skilled in the art which are suitable for a chemical labeling according to the invention are biotin, fluorescein isothiocyanate (FITC) or streptavidin
• enzymes known to the person skilled in the art which are suitable for an enzyme labeling according to the invention are malathyrogenase staphylococcus nuclease ⁇ -5-steroidal isomerase alcohol dehydrogenase ⁇ -glycerol phosphate dehydrogenase, typhosphate isomerase peroxidase ⁇ -alkalase phosphatasease aspatasease Catalase glucose-6-phosphate dehydrogenase glucoamylase luciferase or acetylcholmesterase
• proteins or protein fragments known to the person skilled in the art which are suitable for a protein labeling according to the invention are an N- or C-terminal (H ⁇ S) e, a Myc a FLAG E-tag, Strep-tag a Hamaglute ⁇ in glutathione-Tra ⁇ sferase (GST), Intern with a chitin maltose-forming protein
• isotopes known to the person skilled in the art which are suitable for radioactive isotope labeling according to the invention are 3 H 125 l 131 l 32 P 33 P, 35 S, 1 C, 1 Cr, 57 To, 58 Co, 59 Fe, 75 Se, 152 Eu, 90 Y 67 Cu 217 C ⁇ 211 At 212 Pb 47 Sc or 109 Pb
• isotopes known to the person skilled in the art which are suitable for non-radioactive isotope labeling according to the invention are 2 H or 13 C
• chemiluminescent substances known to the person skilled in the art which are suitable for a chemiluminescent label according to the invention are luminal labeling, isoluminal labeling, aromatic ester labeling, oxal ester labeling.
• fluorescent substances known to the person skilled in the art which are suitable for a fluorescent label according to the invention are 152 Eu fluorescein, isothiocyanate, Rhodamm phycoerythin phycocyanin allophycocyanin o
• Bound nucleic acids can also be further identified or characterized via EST (expressed sequence tags) databases Northern Blot on the detection system according to the invention or by sequencing on the detection system or after targeted release, preferably after prior amplification by means of PCR RT-PCR or cloning
• the present invention therefore also relates to the use of a detection system according to the invention, a method according to the invention or a detection unit according to the invention containing a region (A) with a constant structure and a region (B) adjacent to the region (A) with a variable structure for locating and / or for identifying or characterizing at least one constituent (component (d)) of a sample, in particular of nucleic acids and / or proteins of a sample, or for locating and / or identifying cellular or artificial imaging partners, preferably proteins, peptides, nucleic acids, chemical active substances , preferably organic compounds, pharmacologically active compounds, plant protection agents, toxins, in particular poisons carcinogenic and / or teratogenic substances, herbicides, fungicides or pesticides
• the binding partners of individual proteins can be labeled directly, eg 35 S isotope labeling as spots on the
• Array can be identified Furthermore, it is possible to identify the binding partners of a component (d), preferably a protein, using a labeled component (d) antibody in the form of a sandwich test.
• a particular advantage of this method is that specific interactions of a component (d) from one Pool of interacting substances, for example in a cell extract, can be specifically identified
• the array contains, for example, Fusagene with the glycogen synthase and / or the phosphorylase kinase as an effector
• the effect of the effectors as a substrate can be used in an in vitro assay on the array, for example for the protein kinase which plays an important role in glycogen metabolism can be examined with the help of such an in vitro
• Assays are shown, for example, that the activation of the protein kinase takes place with the addition of cAMP with regard to the phosphorylation of the two effectors.
• the removal of the corresponding phosphate groups on the individual effectors can be examined, for example, by adding the protein phosphatase 1
• the invention further relates to conjugates containing a recognition system comprising components (a) to (c), at least one component (d) and optionally further substances such as substances interacting with component (d), preferably component (d) - antibodies
• conjugates preferably contain fusagens as component (c)
• the components (d) in the conjugates are preferably proteins, peptides, in particular traction factors, receptors, enzymes and / or chemical agents, preferably organic compounds, pharmacologically active compounds, hormones, crop protection agents, toxins, in particular poisons, carcinogenic and / or teratogenic substances, herbicides, fungicides and / or pesticides contain
• FIG. 1 schematically describes the detection system according to the invention comprising a carrier ((1) component (a)) and a detection unit component (b) (2) which is bound to the carrier and which can be bound to the surface of the carrier via a spacer (3), which furthermore is a contains constant region (A) (4) and an adjacent variable region (B) (5), and a component (c) (6) comprising a region complementary to region (A) (4) and (B) (5), which is formed from parts of a suitable linker, for example a nucleic acid linker (8) containing puromycin (7) and from parts of the nucleic acid bound to the linker, here RNA (9). At the nucleic acid-puromycin linker (7, 8) the effector unit (10) is bound
• FIG. 2 schematically describes the identification of a complex consisting of components (a) - (c) using a marker (11) contained in component (c)
• FIG. 3 schematically describes the identification of a complex consisting of components (a) - (d) with the aid of a label, for example contained in component (d) (12), shown here using the example of an effector antibody
• a standard glass slide is first degreased in Aceto ⁇ in an ultrasonic bath for 5 minutes (auxiliary color trough for microbiology). After drying in air, the glass slide is treated with 0 1 M NaOH solution in an ultrasonic bath for 5 minutes
• the amino-modified detection units (components b) can now be immobilized on the silanized glass surface
• the recognition units (components b) immobilized on the chip in this way are synthesized according to standard methods (see below).
• RNA coding for the FLAG, MYC and STREP epitope is produced in accordance with Roberts and Szostak (Proc NatI Acad Sei USA 1997) as follows PCR reaction is amplified with the aid of ⁇ er Taq polymerase (Promega, Cat No M166F) the DNA template sequence shown below (Seq ID No 1) with the two polymers (Seq ID No 2/3)
• the resulting double-stranded DNA product is transcribed into the corresponding RNA sequence (Seq ID No 4) using an in / trans transcription (Promega, Cat No P 1300)
• a linker (Seq ID No 5), which carries a phosphate group at its 5 'terminus and a puromycin residue (PU) at its 3' terminus, 3'-term ⁇ al to the epitope-coding RNA (Seq ID No 4) ligated
• the ligation is carried out with T4 DNA lig gases (MBI Cat No EL 0333) with the help of two sapwood molecules (Seq ID No 6/7) which are mixed in the reaction in a ratio of 80 20%
• NF fluorescein derivative
• RNA (Seq ID No 4) and linker (Seq ID No 5) is now purified from the non-ligated RNA using a denaturing 6% TBE urea gel
• the Fusage ⁇ thus synthesized is now purified to homogeneity via O go d (T) cellulose (Amersham Pharmacia Biotech Cat No 27-5543-02) and subsequently by means of Strep Tacti ⁇ -Sepharose (IBA, Cat No 2-1202-005)
• the recognition units used each consist of a constant region with the sequence 5'-T ⁇ s-3 '(region A) and a variable region (region B) composed of eight nucleotides.
• the following were used for components (b) Sequences selected (Seq ID No 8/9)
• Component (b) 5'-TTTTTTTTTTTTTTTTTTTTTTTGTAGGCGA-3 '(Seq ID No 9)
• component (b) -1 within variable region B has the nucleotide sequence which is complementary to the molecule consisting of RNA (Seq ID No 4) and linker (Seq ID No 5), whereas component (b) -2 has the variable region B has no specificity for the target sequence of this molecule.
• Components (b) were prepared by standard solid-phase DNA synthesis. A 3'-amino-modifier C3 CPG carrier (Glen Research, Cat No 20 -2950-10) or for a 5'-terminal connection on the glass surface
• 5'-amino modifier C6 phosphoramidite (Glen Research, Cat No 10-1906-90) used
• a 50 ⁇ M (in 0 1 M NaOH) solution of components (b) -1/2 is applied to the siliconized glass surface positions 1 and 2, respectively. After incubation for at least 2 hours, the glass surface is washed with warm water for approx. 5 minutes
• the fusagen is recorded in 5 X SCC buffer and transferred to the chip with a cover glass covered and incubated for 5 minutes at 4 ° C
• the chip is washed 3 times with 5 X SSC buffer at room temperature and the fluorescence fluorescence is read out. Finally, it is washed again with 0 5 x SSC buffer and the fluorescence intensity is read out again. It was found that only in the case of perfect hybridization with the Component (b) -1 was able to detect a fluorescence signal and no interactions of the fusagen with the unspecific sequence of component (b) -2 took place
• Example 2 Generation of an Exemplary FLAG, MYC, STREP-Fusion Glass Chip for Detection of Protein-Protein Interactions (Detection of the FLAG Epitope with a Fluorescently Labeled Specific Anti-FLAG Antibody)
• a standard glass slide in acetone is degreased in an ultrasonic bath for 5 minutes (color trough for microbiology). After drying in the air, the glass slide is treated with 0 1 M NaOH solution in the ultrasonic bath for 5 minutes
• the silanized glass objects After washing with 100% ethanol solution in an ultrasonic bath and drying in air, the silanized glass objects are dried for 20 minutes at 80 ° C.
• the amino-modified recognition units (component b) can now be immobilized on the silanized glass surface
• the components (b) immobilized on the chip were synthesized by standard methods (see below).
• the RNA coding for the FLAG MYC and STREP epitope is based on Roberts and Szostak (Proc NatI Acad Sei USA 1997) as follows
• the DNA template sequence (Seq ID No 1) with the two primers (Seq ID No 2/3) is amplified using a Taq polymerase (Promega, Cat No M166F) using a PCR reaction
• RNA sequence (Seq ID No 4) using a wtro transption (Promega, Cat No
• a linker (Seq ID No 10) which carries a phosphate group at its 5-terminus and a puromycin residue (PU) at its 3'-terminus is ligated 3'-term ⁇ nal to the epitope-coding RNA (Seq ID No 4)
• the ligation is preferably carried out using T4 DNA ligase (MBI Cat No EL 0333) with the aid of two splint molecules
• RNA The ligation product consisting of RNA (Seq ID No 4) and linker (Seq ID No).
• RNA (Seq ID No 4) epitope-coding peptide (Seq ID No 4) and linker (Seq ID No 10) is based on Roberts and Szostak (Proc NatI Acad Sei USA 1997) via a wtro-translation (Promega,
• the Fusagen synthesized in this way is then purified to homogeneity using oligo d (T) cellulose (Amersham Pharmacia Biotech Cat No 27-5543-02) and subsequently using Strep Tactin-Sepharose (IBA Cat No 2-1202-005)
• the recognition units used each consist of a constant region with the sequence 5'-T ⁇ s-3 '(region A) and a variable region (region B) composed of eight nucleotides.
• the following were used for components (b) Sequences selected (Seq ID No 8/9) 23
• Component (b) -1 within variable region B has the nucleotide sequence which is complementary to the molecule consisting of RNA (Seq ID No 4) and linker (Seq ID No 10), whereas component (b) -2 has the variable region B has no specificity for the target sequence of this molecule.
• Components (b) were prepared by standard solid-phase DNA synthesis. In the case of immobilization via the 3'-terminus, a 3'-amine modifier C3 CPG carrier (Glen Research Cat No 20-2950-10) or a 5'-amino modifier C6 phosphoramidite (Glen Research, Cat No 10- 1906-90) is used for a 5'-terminal connection on the glass surface.
• the fusion protein is taken up in 5 x SCC buffer and transferred to the individual chip, covered with a cover glass and incubated for 5 minutes at 4 ° C. Then the Chip 3x washed with 5 x SSC buffer at room temperature and a solution of the anti-FLAG antibody (Sigma Immunochemicals, Cat No F 3040) which had previously been fluorescence-labeled (Cy5 Ab Labellmg Kit, Ameramam Pharmacia Biotech Cat No PA 35000) was added and their fluorescence is read out Finally, it is washed again with 0 5 x SSC buffer and the fluorescence intensity is read out again.
• the anti-FLAG antibody Sigma Immunochemicals, Cat No F 3040
• fusagens Two fusagens (components (c)) were synthesized, which could be clearly discriminated against and characterized from one another in a hybrid disruption experiment on the addressable electronic chip.
• fusagings component (c) -1) from example 2
• another but different fusagen is used (Component (c) -2) using a template DNA (Seq ID No 11), two primers (Seq ID No 12/13) and a splint (Seq ID No 14) synthesized consisting of RNA (Seq ID No 15 ), epitope coding peptide (Seq ID No 15) and linker (Seq ID No 10)
• the components (b) immobilized on the electronic chip are biotin-labeled components (b) (Seq ID ⁇ o 16-28), which were obtained by standard D ⁇ A synthesis.
• the immobilization can in each case be 3'-term ⁇ nal or 5'-term ⁇ nal take place
• the components (b) are connected to the chip surface with a biotin modification on the 3'-
• a BiotinTEG CPG carrier (Glen Research Cat Go 20-2955-10) is used for the cnemic D ⁇ A synthesis and the following components (b) with the corresponding biotin modification are synthesized, which also consist of a 15 ⁇ ucleotide-Iange ⁇ thymidine region (region A) and a variable range of 8 nucleotides (region B) exist
• Component (b) -3 and component (b) -4 are respectively their respective variables
• Component (c) -3) and Seq ID No 15 + 10 (component (c) -4) or the Fusagene (component (c) -1 or component (c) -2) are taken up in 50 mM histidine buffer and the respective hybridization experiments on the corresponding chip positions (row column) carried out at room temperature 1 1 component (c) -1 1 2 component (c) -2, 2 1 component (c) -1 2.2 component (c) -2 3 1 component (c) -1 3.2 component (c) -2 1 3 component (c) -3, 2 3 component (c) -4 3.3 no component (c)
• an anti-FLAG antibody Sigma Immunochemicals, Cat No F 3040
• Cy5 Ab Labellmg Kit Amersham Pharmacia Biotech, Cat No PA 35000
• An E-antibody Amersham Pharmacia Biotech Cat No 27- 9412-01 that recognizes the E-tag epitope is placed on positions 2 1 and 2.2. Cy5 Ab Labellmg Kit Amersham Pharmacia Biotech Cat No PA 35000), applied to the chip positions 3, 1
• the fluorescent anti-FLAG antibody or anti-E-tag antibody is applied in order to detect possible non-specific binding events of the antibody

Applications Claiming Priority (3)

Publications (1)

Family

ID=7909147

Family Applications (1)

Country Status (10)

Families Citing this family (4)

Family Cites Families (11)

• 1999
  • 1999-05-25 DE DE19923966A patent/DE19923966C2/de not_active Expired - Fee Related
• 2000
  • 2000-04-01 WO PCT/EP2000/002938 patent/WO2000071747A2/de active Application Filing
  • 2000-04-01 AU AU36591/00A patent/AU3659100A/en not_active Abandoned
  • 2000-05-25 WO PCT/EP2000/004791 patent/WO2000071749A2/de not_active Application Discontinuation
  • 2000-05-25 IL IL14637100A patent/IL146371A0/xx unknown
  • 2000-05-25 CA CA002374438A patent/CA2374438A1/en not_active Abandoned
  • 2000-05-25 EE EEP200100616A patent/EE200100616A/xx unknown
  • 2000-05-25 CN CN00809231A patent/CN1413262A/zh active Pending
  • 2000-05-25 JP JP2000620126A patent/JP2003500066A/ja active Pending
  • 2000-05-25 CZ CZ20014210A patent/CZ20014210A3/cs unknown
  • 2000-05-25 AU AU56760/00A patent/AU5676000A/en not_active Abandoned
  • 2000-05-25 EP EP00941987A patent/EP1185704A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events